Traces of cannabis found in Haribo Cola candy in the Netherlands
Haribo is recalling packs of sweets in the Netherlands after some were found to contain traces of cannabis.
The Dutch Food and Consumer Product Safety Agency (NVWA) warned any potential customers of the 1 kilogram (2.2 pounds) bags of Happy Cola F!ZZ not to eat the sweets because they may cause dizziness.
NVWA spokesperson Saida Ahyad told French news agency AFP that, "Cannabis was found in the cola bottles in question."
The NVWA also said the issue only concerns three bags so far but all stock has been recalled as a precaution, adding that it is working with authorities to investigate the cause of the contamination.
Local Dutch media reported that a family in Twente became "quite ill" after eating the candy and reported the incident to police. After a forensic investigation, police discovered traces of cannabis and alerted the NVWA, according to the media reports.
A Haribo spokesperson told CBS News sister network BBC News it was working with police to "establish the facts around the contamination."
Haribo Vice-President of Marketing told AFP the incident is "a live issue and we are working closely with the Dutch authorities to support their investigation and establish the facts."
The recall applies to the items under the production code L341-4002307906, with a best before date of January 2026.
E.l.f. Beauty calls Hailey Bieber an industry disruptor amid Rhode sale
These 3 record breakers have one thing in common
Reporter's Notebook: John Dickerson reflects on his spelling woes
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Chan Chun Sing meets Timor-Leste president, foreign defence leaders
SINGAPORE – Defence Minister Chan Chun Sing met several of his counterparts on the sidelines of the 22nd Shangri-La Dialogue on May 30, and reaffirmed Singapore's friendly bilateral defence ties with their countries, the Ministry of Defence said. The minister called on Timor-Leste President Jose Ramos-Horta, and they exchanged views on regional security developments and ways to enhance bilateral defence cooperation, said Mindef. Mr Chan also met Malaysian Defence Minister Mohamed Khaled Nordin, and both ministers reaffirmed the warm and longstanding bilateral relationship. They discussed regional security issues and cooperation between their countries in multilateral platforms such as the Asean Defence Ministers' Meeting (ADMM), ADMM-Plus and the Five Power Defence Arrangements. 'Singapore and Malaysia's defence establishments interact regularly across a wide range of activities, including bilateral and multilateral exercises, visits, professional exchanges, and cross-attendance of courses,' said Mindef. 'These interactions strengthen mutual understanding and professional ties.' In a meeting Mr Chan had with Brunei's Minister at the Prime Minister's Office and Minister of Defence II Haji Awang Halbi Haji Mohd Yussof, they discussed bilateral cooperation as well as engagement through multilateral platforms such as the ADMM and ADMM-Plus. Singapore's and Brunei's militaries have regular interactions through high-level visits, professional exchanges, cross-attendance of courses and bilateral exercises, which strengthen ties and enhance professionalism, said Mindef. Both countries will mark the 50th anniversary of defence relations in 2026. Mr Chan also met Philippine Secretary of National Defence Gilberto Teodoro Jr, and they expressed their commitment to continue working together through the ADMM and ADMM-Plus meetings. They also discussed avenues to further defence cooperation between their countries. In addition, Mr Chan met French Minister of the Armed Forces Sebastien Lecornu. Mr Chan expressed appreciation for France's support for the Republic of Singapore Air Force training at Cazaux Air Base since 1998. Both ministers also exchanged views on security priorities and geopolitical developments, said Mindef. The two defence ministers had earlier on May 30 signed three agreements to expand cooperation between Singapore and France in emerging and advanced areas of defence technology, such as quantum and artificial intelligence. The ceremony was witnessed by Prime Minister Lawrence Wong and French President Emmanuel Macron, who is on a state visit to Singapore. The state visit comes as Singapore and France mark 60 years of diplomatic relations. During the visit, PM Wong and Mr Macron upgraded bilateral relations to a Comprehensive Strategic Partnership, the Republic's first with a European country. Mr Chan's meetings took place at the Shangri-La Hotel, where regional and global defence leaders have gathered for the annual Shangri-La Dialogue, Asia's premier security summit. The dialogue, being held from May 30 to June 1, brings together defence ministers, military chiefs and security experts from around the world to discuss key security issues in the Asia-Pacific region. Source: The Straits Times © SPH Media Limited. Permission required for reproduction Discover how to enjoy other premium articles here
Yahoo
41 minutes ago
- Yahoo
Sanofi (ENXTPA:SAN) Reports Positive Phase 3 Results for Itepekimab in COPD Trial
Sanofi announced that its AERIFY-1 trial with Regeneron Pharmaceuticals successfully met its primary endpoint, indicating progress in COPD treatment. Despite this positive news, the company's share price fell 5% over the last week, contrasting with a 2% rise in the broader market. This decline may reflect investors' reactions to other company initiatives, such as its partnership with Stagecoach Performing Arts to raise awareness of autoimmune Type 1 diabetes. These positive developments, although promising, were not enough to counterbalance the broader market's upward trend, contributing weight against Sanofi's price movement. Buy, Hold or Sell Sanofi? View our complete analysis and fair value estimate and you decide. Uncover the next big thing with financially sound penny stocks that balance risk and reward. The recent successful completion of Sanofi's AERIFY-1 trial could have a positive impact on its revenue and earnings forecasts by strengthening its position in the COPD treatment market. However, despite these promising developments, the company's share price experienced a 5% decline in the past week, contrasting with the broader market's 2% rise. This movement might reflect investor reactions to other company initiatives, such as the partnership with Stagecoach Performing Arts, and broader market trends. Looking at a longer-term context, Sanofi's shares have delivered a total return of 19.59% over the past five years. Recent performance has exceeded the French Pharmaceuticals industry and market, which returned 4% and 4.5% declines respectively over the last year. Such outperformance indicates resilience amidst industry challenges and market volatility. Please consider the current share price of €95.9 against the consensus price target of €117.17, indicating a potential upside potential of approximately 18.5%. This price target is based on expectations of revenue reaching €51.2 billion and earnings of €10.2 billion by 2028, trading on a PE ratio of 16.1x. Analysts are assuming that Sanofi will enhance its growth trajectory driven by its innovative treatments and efficient operational strategies. Assess Sanofi's previous results with our detailed historical performance reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:SAN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
41 minutes ago
- Yahoo
French scientist Etienne-Emile Baulieu, inventor of the abortion pill, dies at 98
ROME (AP) — French scientist Etienne-Emile Baulieu, best known as the inventor of the abortion pill, died on Friday aged 98 at his home in Paris, his institute said in a statement. Both a doctor and a researcher, Baulieu was known around the world for the scientific, medical and social significance of his work on steroid hormones. 'His research was guided by his attachment to the progress made possible by science, his commitment to women's freedom, and his desire to enable everyone to live better, longer lives,' the Institut Baulieu said in the statement posted on its website. Born Etienne Blum in Strasbourg on Dec. 12, 1926, he took the name 'Émile Baulieu' when he joined the French Resistance against the Nazi occupation at the age of 15. An endocrinologist with a doctorate in medicine completed in 1955 and one in science eight years later, in 1963 Baulieu founded a pioneering research unit working on hormones at INSERM, the French institute for health and medical research. He remained as head of the unit until 1997. He is best known for his development, in 1982, of RU 486, the so-called 'abortion pill' that changed the lives of millions of women throughout the world, offering them the possibility of voluntary medical termination of pregnancy, in physical and psychological safety. The Institut Baulieu said it was 'a non-invasive method, less aggressive and less delayed than surgery,' noting that following his discovery the researcher faced fierce criticism and even threats from opponents of women's abortion rights. 'Even today, access to this method is opposed, banned in some countries, and is currently being challenged in the United States, where it is the most widely used abortion method,' the institute added. Baulieu's research into DHEA, a hormone whose secretion and anti-aging activity he had discovered, led him to work on neurosteroids -- or steroids of the nervous system. He also developed an original treatment to combat depression, for which a clinical trial is currently underway in several university hospitals. In 2008, he founded the Institut Baulieu to understand, prevent and treat neurodegenerative diseases such as Alzheimer's. Honored with the grand crosses of the Légion d'honneur (legion of honor) and the Ordre national du Mérite (national order of merit), he was elected to the French Academy of Sciences in 1982, which he chaired in 2003 and 2004. He was a member of the national advisory committee on life sciences and health (1996-2002) and received numerous awards, both in France and abroad. French President Emmanuel Macron paid tribute to Baulieu in a post on X, calling him 'a beacon of courage' and 'a progressive mind who enabled women to win their freedom.' 'Few French people have changed the world to such an extent,' he added. After the death of his first wife, Yolande Compagnon, he remarried, to Simone Harari Baulieu. He is survived by three children, eight grandchildren and nine great-grandchildren, his institute said.
